Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease

References

• Anderson BE, McNiff JM, Jain D, et al. (2005). Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood, 105, 2227–34
   PubMed Web of Science ®Google Scholar
• Broady R, Yu J, Chow V, et al. (2010). Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood, 116, 5748–51
   Google Scholar
• Carlson MJ, West ML, Coghill JM, et al. (2009). In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood, 113, 1365–74
   PubMed Web of Science ®Google Scholar
• Chen X, Das R, Komorowski R, et al. (2010). Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. Biol Blood Marrow Transplant, 16, 123–8
   Google Scholar
• Cho BS, Lim JY, Yahng SA, et al. (2012). Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. Annals of hematology, 91, 439–48
   Google Scholar
• Cooke KR, Kobzik L, Martin TR, et al. (1996). An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood, 88, 3230–9
   PubMed Web of Science ®Google Scholar
• Dander E, Balduzzi A, Zappa G, et al. (2009). Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation, 88, 1261–72
   PubMed Web of Science ®Google Scholar
• Dong C. (2006). Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol, 6, 329–33
   PubMed Web of Science ®Google Scholar
• Fraser CJ, Bhatia S, Ness K, et al. (2006). Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the Bone Marrow Transplant Survivor Study. Blood, 108, 2867–73
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. (2010). Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med, 363, 2091–101
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Aljurf M, et al. (2010). Hematopoietic stem cell transplantation: A global perspective. JAMA, 303, 1617–24
   PubMed Web of Science ®Google Scholar
• Hill GR, Cooke KR, Teshima T, et al. (1998). Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest, 102, 115–23
   PubMed Web of Science ®Google Scholar
• Howell CD, De Victor D, Li J, et al. (1995). Liver T cell subsets and adhesion molecules in murine graft-versus-host disease. Bone Marrow Transplant, 16, 139–45
   Google Scholar
• Iclozan C, Yu Y, Liu C, et al. (2010). T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant, 16, 170–8
   PubMed Web of Science ®Google Scholar
• Jenq RR, van den Brink MR. (2010). Allogeneic haematopoietic stem cell transplantation: Individualized stem cell and immune therapy of cancer. Nat Rev Cancer, 10, 213–21
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Anderson BE, McNiff JM, et al. (2004). Target antigens determine graft-versus-host disease phenotype. J Immunol, 173, 5467–75
   PubMed Web of Science ®Google Scholar
• Kappel LW, Goldberg GL, King CG, et al. (2009). IL-17 contributes to CD4-mediated graft-versus-host disease. Blood, 113, 945–52
   PubMed Web of Science ®Google Scholar
• Kim J, Kim HJ, Park K, et al. (2007). Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood, 110, 776–82
   PubMed Web of Science ®Google Scholar
• Kolls JK, Linden A. (2004). Interleukin-17 family members and inflammation. Immunity, 21, 467–76
   PubMed Web of Science ®Google Scholar
• Lee JW, Joachim Deeg H. (2008). Prevention of chronic GVHD. Best Pract Res Clin Haematol, 21, 259–70
   Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. (2003). Chronic graft-versus-host disease. Biol Blood Marrow Transplant, 9, 215–33
   PubMed Web of Science ®Google Scholar
• Li J, Helm K, Howell CD. (1996). Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation, 62, 1621–8
   Google Scholar
• McCormick LL, Zhang Y, Tootell E, Gilliam AC. (1999). Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol, 163, 5693–9
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. (2009). Interleukin-17 and type 17 helper T cells. N Engl J Med, 361, 888–98
   PubMed Web of Science ®Google Scholar
• Nishimori H, Maeda Y, Teshima T, et al. (2012). Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood, 119, 285–95
   Google Scholar
• Radojcic V, Pletneva MA, Yen HR, et al. (2010). STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol, 184, 764–74
   Google Scholar
• Ratajczak P, Janin A, Peffault de Latour R, et al. (2010). Th17/Treg ratio in human graft-versus-host-disease. Blood, 116, 1165–71
   PubMed Web of Science ®Google Scholar
• Sakoda Y, Hashimoto D, Asakura S, et al. (2007). Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood, 109, 1756–64
   PubMed Web of Science ®Google Scholar
• Svegliati S, Olivieri A, Campelli N, et al. (2007). Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 110, 237–41
   PubMed Web of Science ®Google Scholar
• Teshima T. (2011). Th1 and Th17 join forces for acute GVHD. Blood, 118, 4765–7
   PubMed Web of Science ®Google Scholar
• Wolff D, Gerbitz A, Ayuk F, et al. (2010). Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant, 16, 1611–28
   PubMed Web of Science ®Google Scholar
• Yi T, Chen Y, Wang L, et al. (2009). Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 114, 3101–12
   PubMed Web of Science ®Google Scholar
• Yi T, Zhao D, Lin CL, et al. (2008). Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood, 112, 2101–10
   PubMed Web of Science ®Google Scholar
• Zhang C, Todorov I, Zhang Z, et al. (2006). Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood, 107, 2993–3001
   PubMed Web of Science ®Google Scholar
• Zhang Y, McCormick LL, Desai SR, et al. (2002). Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol, 168, 3088–98
   PubMed Web of Science ®Google Scholar
• Zhou L, Askew D, Wu C, Gilliam AC. (2007). Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol, 127, 281–92
   PubMed Web of Science ®Google Scholar